{'fraction_non_alphanumeric': 0.04084507042253521, 'fraction_numerical': 0.01971830985915493, 'mean_word_length': 5.348214285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Last crusade against HCV: Direct‐acting antiviral treatment for marginalized populations

We read with interest the article by Bajis et al, reporting hepatitis C virus (HCV) testing, treatment, and outcome for homeless people in Sydney.1 Among the 202 participants, 23% (n=47) had detectable HCV RNA and 6% had cirrhosis. Out of 23 HCV patients who started direct-acting antiviral agents (DAA) treatment, only 65% had a documented sustained virologic response (SVR) outcome.1 This study is important because marginalized populations, such as the homeless, and people with alcohol or polysubstance dependency issues, have a high HCV infection burden. This article is protected by copyright. All rights reserved.